Standout Papers

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inad... 2004 2026 2011 2018 815
  1. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE (2004)
    Marc Humbert, Richard Beasley et al. Allergy

Immediate Impact

3 from Science/Nature 73 standout
Sub-graph 1 of 20

Citing Papers

GZMK-expressing CD8+ T cells promote recurrent airway inflammatory diseases
2025 StandoutNature
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
2 intermediate papers

Works of K. Surrey being referenced

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
2004 Standout

Author Peers

Author Last Decade Papers Cites
K. Surrey 1080 797 637 9 1.1k
K.M. Beeh 822 644 420 10 868
Stephen T. Holgate 1009 671 323 9 1.2k
T.F. Reiss 909 761 317 10 1000
Fiona Nelson 1042 776 278 8 1.2k
Marijke Amelink 1103 880 227 13 1.2k
Gun Almqvist 721 419 247 16 879
Sandhia Ponnarambil 1241 858 339 14 1.4k
Philippe Godard 724 683 146 12 889
R P Young 687 344 390 17 1.3k
Julie Olsson 576 582 208 13 1.1k

All Works

Loading papers...

Rankless by CCL
2026